Abstract Details

Title Risk Factors for Cerebral Venous Sinus Thrombisis in the past Five Years at Hahnemann University Hospital

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) P02 - (-)

Poster/Presentation
Number 036

Objective

Background BACKGROUND: CVST is a rare but serious and treatable condition. It is an uncommon and often unrecognized type of stroke that affects approximately 5 people per million annually.

Design/Methods DESIGN/METHODS: We performed a retrospective analysis of all patients who presented to HUH in the past 10 years that were diagnosed with CVST during their hospitalization and reviewed their risk factors, clinical findings and prognosis.

Results RESULTS: A total of 30 patients were identified. A female predominance of 2:1 with a mean age of 43 years was seen. A risk factor was identified in 83% of patients. The most common risk factor was systemic disease. The most common presenting symptom was headache, which was present in 60% of the patients. 33% of patients had a normal physical exam. Only 13% of patients had papilledema. The most common sinus involved was the transverse sinus, which was involved 43% of the time. 90% of the patients were discharged home.

Conclusions CONCLUSIONS: In our case series 83% of patients had at least one risk factor. In the largest case series, a risk factor was identified 80% of the time. Headache was the most common presenting symptom of CVST. 60% of our patients presented with headache as their chief complaint, which is consistent with the largest case series where 70% of patients presented with a headache. Although papilledema is often thought to be a common finding, only 13% of our patients had this finding. However, in the largest case series to date 30% of people had papilledema. CVST needs to be considered in the differential diagnosis of headaches even in the absence of papilledema.

Authors/Disclosures
Tooba Fayyaz, DO, FAAN PRESENTER	No disclosure on file
Yedatore S. Venkatesh, MD, FAAN (University of SC School of Medicine)	Dr. Venkatesh has nothing to disclose.
	No disclosure on file
Thomas A. Berger, MD (Dept. of Neurology, Medical University of Vienna)	Prof. Berger has received personal compensation in the range of $10,000-$49,999 for serving as a speaker at scientific meetings and participant of local and international advisory boards with various companies producing and markerting treatments for multiple sclerosis (Almirall, Biogen, Biologix, Bionorica, Celgene-BMS, Merck, Novartis, Roche, Sanofi-Genzyme, TG Therapeutics, UCB).

��ɫ��

��ɫ��